arrow
J

José Luis Alonso-Romero

oncology
H指数:18
被引数:1,007

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

miR-106b-5p as a Central Regulator of Cancer Progression and Chemotherapy-Induced Cardiotoxicity: From Molecular Mechanisms to Clinical Translation

miR-106b-5p作为癌症进展和化疗诱导的心脏毒性中心调控因子:从分子机制到临床转化

2026-03-030
OAAI
Translational and real-world evidence of trastuzumab biosimilar CT-P6 plus pertuzumab in neoadjuvant HER2-positive early breast cancer
2026-01-200
OAAI
Functional characterization of splice variants in hereditary breast and ovarian cancer susceptibility genes

遗传性乳腺癌和卵巢癌易感基因剪接变体的功能表征

2025-12-180
PRE
Bone Health in Metastatic Hormone-Sensitive Prostate Cancer: Where We Stand and Where We Can Improve

转移性激素敏感性前列腺癌的骨骼健康:我们目前的进展及可改进之处

2025-12-130
OAAI
Outcomes of Kidney Transplantation from Deceased Donors with Severe Acute Kidney Injury (AKIN Stage 3): A Preliminary Single-Centre Analysis

deceased donors with severe acute kidney injury (AKIN Stage 3): A Preliminary Single-Centre Analysis

2025-09-140
OAAI
Randomized Phase II trial evaluating three antidiarrhoeal prophylaxis strategies in patients with HER2+/HR+ early breast cancer treated with extended adjuvant neratinib (DIANER GEICAM/2018-06)
2024-05-020
PRE
Lower pre-treatment B-cell gene expression signatures correspond with improved overall survival with palbociclib plus endocrine therapy in HR+/HER2-metastatic breast cancer: a biomarker analysis from the GEICAM/2013-02 PEARL trial
2024-05-020
PRE
Deciphering pregnancy-associated breast cancer: distinctive molecular profile and clinical implications from GEICAM/2017-07 EMBARCAM study
2024-05-020
PRE
Preventing alpelisib-related hyperglycaemia in HR+/HER2-/ PIK3CA-mutated advanced breast cancer using metformin (METALLICA): a multicentre, open-label, single-arm, phase 2 trial

使用二甲双胍预防HR /HER2-/ PIK3CA-mutated晚期乳腺癌中与alpelisib相关的高血糖症 (METALLICA): 一项多中心,开放标签,单臂,2期试验

2024-05-011
OAAI
Metformin (MET) for the prevention of Alpelisib (ALP)-related Hyperglycemia (HG) in PIK3CA-mutated, Hormone Receptor-Positive (HR[+]) HER2-Negative (HER2[-]) Advanced Breast Cancer (ABC): The METALLICA study
2023-03-016
PRE
Treatment strategies for advanced triple negative breast cancer patients as per routine clinical practice: analysis from the observational study GEICAM/2014-03 (RegistEM)
2023-03-010
PRE
Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study

PEARL研究中激素受体阳性、HER2-negative转移性乳腺癌绝经后患者接受palbociclib联合内分泌治疗与卡培他滨治疗的总生存率比较

2022-06-0112
OA
Pembrolizumab plus eribulin in hormone receptore-positive, HER2-negative, locally recurrent or metastatic breast cancer (KELLY): An open-label, multicentre, single-arm, phase II trial

Pembrolizumab联合eribulin治疗激素受体阳性,HER2-negative,局部复发或转移性乳腺癌 (KELLY): 一项开放标签,多中心,单臂,II期试验

2021-05-0129
PREAI